Fizazi K - Search Results

1

Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model.

Faugeroux V, Pailler E, Oulhen M, Deas O, Brulle-Soumare L, Hervieu C, Marty V, Alexandrova K, Andree KC, Stoecklein NH, Tramalloni D, Cairo S, NgoCamus M, Nicotra C, Terstappen LWMM, Manaresi N, Lapierre V, Fizazi K, Scoazec JY, Loriot Y, Judde JG, Farace F. Faugeroux V, et al. Among authors: fizazi k. Nat Commun. 2020 Apr 20;11(1):1884. doi: 10.1038/s41467-020-15426-2. Nat Commun. 2020. PMID: 32313004 Free PMC article.

2

[Management of localized germ-cell tumours of the testis].

Loriot Y, Fizazi K. Loriot Y, et al. Among authors: fizazi k. Rev Prat. 2007 Feb 28;57(4):379-84. Rev Prat. 2007. PMID: 17455739 Review. French.

3

[Management of clinical stage I testicular germ cell tumours].

Loriot Y, Fizazi K. Loriot Y, et al. Among authors: fizazi k. Bull Cancer. 2007 May;94(5):439-48. Bull Cancer. 2007. PMID: 17535781 Free article. Review. French.

4

Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features.

Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, Fizazi K. Loriot Y, et al. Among authors: fizazi k. Ann Oncol. 2009 Apr;20(4):703-8. doi: 10.1093/annonc/mdn694. Epub 2009 Jan 29. Ann Oncol. 2009. PMID: 19179557 Free article.

5

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.

Fizazi K, Beuzeboc P, Lumbroso J, Haddad V, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Theodore C, Loriot Y, Tournay E, Bouzy J, Laplanche A. Fizazi K, et al. J Clin Oncol. 2009 May 20;27(15):2429-35. doi: 10.1200/JCO.2008.18.9811. Epub 2009 Apr 13. J Clin Oncol. 2009. PMID: 19364971 Clinical Trial.

6

[New drugs in metastatic castration-resistant prostate cancer].

Albiges L, Loriot Y, Gross-Goupil M, de La Motte Rouge T, Blesius A, Escudier B, Massard C, Fizazi K. Albiges L, et al. Among authors: fizazi k. Bull Cancer. 2010 Jan;97(1):149-59. doi: 10.1684/bdc.2009.1023. Bull Cancer. 2010. PMID: 20022854 Free article. French.

7

The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer.

Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, Chauchereau A, Fizazi K. Loriot Y, et al. Among authors: fizazi k. Eur J Cancer. 2010 Jul;46(10):1770-2. doi: 10.1016/j.ejca.2010.04.010. Epub 2010 May 17. Eur J Cancer. 2010. PMID: 20483588

8

How to select targeted therapy in renal cell cancer.

Escudier B, Albiges L, Blesius A, Loriot Y, Massard C, Fizazi K. Escudier B, et al. Among authors: fizazi k. Ann Oncol. 2010 Oct;21 Suppl 7:vii59-62. doi: 10.1093/annonc/mdq371. Ann Oncol. 2010. PMID: 20943644 Free article. Review.

9

A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas.

Farace F, Massard C, Vimond N, Drusch F, Jacques N, Billiot F, Laplanche A, Chauchereau A, Lacroix L, Planchard D, Le Moulec S, André F, Fizazi K, Soria JC, Vielh P. Farace F, et al. Among authors: fizazi k. Br J Cancer. 2011 Sep 6;105(6):847-53. doi: 10.1038/bjc.2011.294. Epub 2011 Aug 9. Br J Cancer. 2011. PMID: 21829190 Free PMC article.

10

Carcinomas of an unknown primary origin--diagnosis and treatment.

Massard C, Loriot Y, Fizazi K. Massard C, et al. Among authors: fizazi k. Nat Rev Clin Oncol. 2011 Nov 1;8(12):701-10. doi: 10.1038/nrclinonc.2011.158. Nat Rev Clin Oncol. 2011. PMID: 22048624 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

518 results

Search Page